Trial · NCT00720083
Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
NCT00720083, Phase 2, Terminated, Radiation Therapy Oncology Group; results first posted 2013-05-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer. Trials, record NCT00720083. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00720083
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer
- NCT number
- NCT00720083
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Radiation Therapy Oncology Group
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, vandetanib, radiation therapy
- First posted
- 2008-07-22
- Last updated
- 2015-11-17
- Results first posted
- 2013-05-08
- Limitations and caveats
- This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease-free Survival | From randomization to date of failure (local, regional, or distant progression, or death) or last follow-up. Analysis occurs after 78 failures have been reported. | This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease-free Survival | From randomization to date of failure (local, regional, or distant progression, or death) or last follow-up. Analysis occurs after 78 failures have been reported. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | RT + Cisplatin | 17 | |
| Overall Study | STARTED | RT + Cisplatin + Vandetanib | 15 | |
| Overall Study | COMPLETED | RT + Cisplatin | 16 | |
| Overall Study | COMPLETED | RT + Cisplatin + Vandetanib | 13 | |
| Overall Study | NOT COMPLETED | RT + Cisplatin | 1 | |
| Overall Study | NOT COMPLETED | RT + Cisplatin + Vandetanib | 2 |
Source ClinicalTrials.gov
Adverse events240
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | RT+ Cisplatin | 9 | 16 | |
| other | Anemia | Blood and lymphatic system disorders | RT + Cisplatin + Vandetanib | 1 | 13 | |
| other | Hemolysis | Blood and lymphatic system disorders | RT+ Cisplatin | 1 | 16 | |
| other | Hemolysis | Blood and lymphatic system disorders | RT + Cisplatin + Vandetanib | 0 | 13 | |
| other | Ear and labyrinth disorders - Other | Ear and labyrinth disorders | RT+ Cisplatin | 1 | 16 | |
| other | Ear and labyrinth disorders - Other | Ear and labyrinth disorders | RT + Cisplatin + Vandetanib | 0 | 13 | |
| other | Ear pain | Ear and labyrinth disorders | RT+ Cisplatin | 2 | 16 | |
| other | Ear pain | Ear and labyrinth disorders | RT + Cisplatin + Vandetanib | 0 | 13 | |
| other | Hearing impaired | Ear and labyrinth disorders | RT+ Cisplatin | 5 | 16 | |
| other | Hearing impaired | Ear and labyrinth disorders | RT + Cisplatin + Vandetanib | 0 | 13 |
1 to 10 of 240Source ClinicalTrials.gov
See all 240 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | RT+ Cisplatin | ||
| Total, all-cause mortality | RT + Cisplatin + Vandetanib | ||
| Total, other adverse events | RT+ Cisplatin | 16 | 16 |
| Total, other adverse events | RT + Cisplatin + Vandetanib | 12 | 13 |
| Total, serious adverse events | RT+ Cisplatin | 6 | 16 |
| Total, serious adverse events | RT + Cisplatin + Vandetanib | 4 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| RT+ Cisplatin vs RT + Cisplatin + Vandetanib: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00720083
GET https://conductscience.org/api/trials/v1/NCT00720083/events?page=2